Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)
Hong Kong · Delayed Price · Currency is HKD 5.38
+0.03 (0.56%)
Oct 31, 2025, 4:08 PM HKT
HKG:9989 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 5,384 | 5,259 | 5,431 | 7,097 | 6,318 | 5,284 | Upgrade |
Other Revenue | - | - | - | 61.92 | 47.33 | 48.04 | Upgrade |
| 5,384 | 5,259 | 5,431 | 7,159 | 6,365 | 5,332 | Upgrade | |
Revenue Growth (YoY) | -0.96% | -3.17% | -24.14% | 12.48% | 19.38% | 15.30% | Upgrade |
Cost of Revenue | 3,674 | 3,520 | 4,490 | 4,861 | 4,367 | 3,300 | Upgrade |
Gross Profit | 1,711 | 1,739 | 940.9 | 2,298 | 1,998 | 2,032 | Upgrade |
Selling, General & Admin | 1,033 | 1,028 | 1,192 | 975.69 | 850.68 | 821.65 | Upgrade |
Research & Development | 45.85 | - | - | 252.14 | 221.1 | 160.01 | Upgrade |
Other Operating Expenses | -14.26 | -26.66 | -34.49 | 22.73 | 20.96 | 26.07 | Upgrade |
Operating Expenses | 1,069 | 993.5 | 1,158 | 1,299 | 1,165 | 1,018 | Upgrade |
Operating Income | 641.55 | 745.82 | -217.29 | 998.55 | 833.53 | 1,014 | Upgrade |
Interest Expense | -350.5 | -141.19 | -223.22 | -235.24 | -201.63 | -247.72 | Upgrade |
Interest & Investment Income | - | 104.2 | 75.95 | 54.14 | 54.86 | 301.79 | Upgrade |
Earnings From Equity Investments | -141.82 | -141.82 | -447.95 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -12.84 | -12.84 | 85.87 | 186.33 | -205.04 | -248.83 | Upgrade |
Other Non Operating Income (Expenses) | 105.6 | -72.08 | -30.71 | -32.55 | -46.18 | -30.47 | Upgrade |
EBT Excluding Unusual Items | 241.99 | 482.09 | -757.34 | 971.23 | 435.53 | 788.38 | Upgrade |
Impairment of Goodwill | - | - | -68.16 | - | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 401.06 | 315.07 | 16.2 | -176.91 | -226.82 | 494.45 | Upgrade |
Gain (Loss) on Sale of Assets | 0.63 | - | - | -2.76 | -5.1 | 0.38 | Upgrade |
Asset Writedown | -142.3 | -55.37 | -44.52 | -0.42 | -1.1 | -0.24 | Upgrade |
Other Unusual Items | -20.76 | -15.56 | -74.52 | 38.71 | 19.75 | 44.87 | Upgrade |
Pretax Income | 480.63 | 726.23 | -928.33 | 829.85 | 222.26 | 1,328 | Upgrade |
Income Tax Expense | 82.15 | 101.31 | -126.18 | 114.82 | -11.12 | 306.2 | Upgrade |
Earnings From Continuing Operations | 398.48 | 624.92 | -802.16 | 715.04 | 233.38 | 1,022 | Upgrade |
Minority Interest in Earnings | 21.72 | 21.82 | 18.9 | 12.39 | 7.4 | 2.58 | Upgrade |
Net Income | 420.2 | 646.74 | -783.26 | 727.43 | 240.79 | 1,024 | Upgrade |
Net Income to Common | 420.2 | 646.74 | -783.26 | 727.43 | 240.79 | 1,024 | Upgrade |
Net Income Growth | - | - | - | 202.10% | -76.49% | -3.32% | Upgrade |
Shares Outstanding (Basic) | 1,470 | 1,470 | 1,478 | 1,468 | 1,467 | 1,353 | Upgrade |
Shares Outstanding (Diluted) | 1,470 | 1,470 | 1,478 | 1,468 | 1,467 | 1,353 | Upgrade |
Shares Change (YoY) | -0.56% | -0.54% | 0.67% | 0.05% | 8.42% | 8.51% | Upgrade |
EPS (Basic) | 0.29 | 0.44 | -0.53 | 0.50 | 0.16 | 0.76 | Upgrade |
EPS (Diluted) | 0.29 | 0.44 | -0.53 | 0.50 | 0.16 | 0.76 | Upgrade |
EPS Growth | - | - | - | 201.95% | -78.32% | -10.90% | Upgrade |
Free Cash Flow | 1,689 | 1,995 | -39.22 | -979.03 | -200.49 | -175.21 | Upgrade |
Free Cash Flow Per Share | 1.15 | 1.36 | -0.03 | -0.67 | -0.14 | -0.13 | Upgrade |
Dividend Per Share | 0.250 | 0.250 | - | 0.100 | 0.035 | 0.150 | Upgrade |
Dividend Growth | - | - | - | 185.71% | -76.67% | -16.67% | Upgrade |
Gross Margin | 31.77% | 33.07% | 17.32% | 32.10% | 31.39% | 38.11% | Upgrade |
Operating Margin | 11.92% | 14.18% | -4.00% | 13.95% | 13.10% | 19.01% | Upgrade |
Profit Margin | 7.80% | 12.30% | -14.42% | 10.16% | 3.78% | 19.21% | Upgrade |
Free Cash Flow Margin | 31.37% | 37.93% | -0.72% | -13.68% | -3.15% | -3.29% | Upgrade |
EBITDA | 891.32 | 1,027 | 105.61 | 1,272 | 1,103 | 1,287 | Upgrade |
EBITDA Margin | 16.55% | 19.53% | 1.94% | 17.77% | 17.34% | 24.14% | Upgrade |
D&A For EBITDA | 249.77 | 281.11 | 322.89 | 273.87 | 269.92 | 273.73 | Upgrade |
EBIT | 641.55 | 745.82 | -217.29 | 998.55 | 833.53 | 1,014 | Upgrade |
EBIT Margin | 11.92% | 14.18% | -4.00% | 13.95% | 13.10% | 19.01% | Upgrade |
Effective Tax Rate | 17.09% | 13.95% | - | 13.84% | - | 23.06% | Upgrade |
Revenue as Reported | 125.54 | - | - | 7,159 | 6,365 | 5,332 | Upgrade |
Advertising Expenses | - | - | - | 23.2 | 18.04 | 11.66 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.